Results 131 to 140 of about 69,057 (285)

Controversies in NEN: An ENETS position statement on the treatment of patients with Grade 3 well‐differentiated neuroendocrine tumours of the gastro‐enteropancreatic tract

Journal of Neuroendocrinology, EarlyView.
Abstract Grade 3 neuroendocrine tumours (NET G3) represent approximately 20% of high‐grade neuroendocrine neoplasms, and the recent identification of this entity has given rise to many unanswered questions relating to clinical management. The prognosis for these patients is worse than for those with Grade 1–2 well‐differentiated NET, but better than ...
Mairéad G. McNamara, Halfdan Sorbye, Nehara Begum, Emanuel Christ, Nicola Fazio, Lynnette Fernandez‐Cuesta, Rocio Garcia‐Carbonero, Gregory Kaltsas, Atsuko Kasajima, Ramon Salazar, Ernst Jan M. Speel, Andreas Kjaer   +11 more
wiley   +1 more source

Somatostatin Receptor 2-Targeted PET Radiotracers Shine in Assessing Inflammatory Activity in Large Vessel Vasculitis. [PDF]

J Am Coll Cardiol, 2023
Tawakol A, Osborne MT.
europepmc   +1 more source

Supplementary Figure 3 from ¹⁷⁷Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer

, 2023
Shilpa Thakur, Brianna Daley, Corina Millo, Craig Cochran, Orit Jacobson, Huiyan Lu, Zhantong Wang, Dale O. Kiesewetter, Xiaohong Chen, Vasyl Vasko, Joanna Kłubo-Gwieździńska   +10 more
openalex   +1 more source

Systematic review and meta‐analysis of the efficacy and safety of [177Lu]Lu‐edotreotide ([177Lu]Lu‐DOTATOC) for the treatment of neuroendocrine tumors

Journal of Neuroendocrinology, EarlyView.
Abstract [177Lu]Lu‐edotreotide is a radiopharmaceutical therapy (RPT) targeting somatostatin receptors, which are commonly overexpressed on neuroendocrine tumors (NETs). This systematic literature review and meta‐analysis describes the efficacy and safety of [177Lu]Lu‐edotreotide in patients with NETs.
Richard P. Baum, Julia G. Fricke, Tristan Ruhwedel, Holger Amthauer, Erika Patricia Azorin‐Vega, Dieter Hörsch, Riccardo Laudicella, Vikalp Maheshwari, Martin A. Walter, Berna Degirmenci Polack, Simon F. Spiegl, Guillaume P. Nicolas   +11 more
wiley   +1 more source

Structural insights into the activation of somatostatin receptor 2 by cyclic SST analogues. [PDF]

Cell Discov, 2022
Bo Q, Yang F, Li Y, Meng X, Zhang H, Zhou Y, Ling S, Sun D, Lv P, Liu L, Shi P, Tian C.   +11 more
europepmc   +1 more source

Somatostatin analogs in neuroendocrine tumors with Ki‐67 index of ≥10%

Journal of Neuroendocrinology, EarlyView.
Abstract Somatostatin analogs (SSAs) are an established first‐line therapy in intestinal and pancreatic neuroendocrine tumors (NETs). Based on Phase III studies, their use is recommended in NET with a Ki‐67 index of up to 10%. The effect of first‐line SSA therapy on differentiated NET with a Ki‐67 index ≥10% is poorly understood.
Johanna Braegelmann, Annie Mathew, Boerge Schmidt, Hamza Kalisch, Wolfgang P. Fendler, Dagmar Führer‐Sakel, Harald Lahner   +6 more
wiley   +1 more source

Expression and Functional Analysis of Dopamine Receptor Subtype 2 and Somatostatin Receptor Subtypes in Canine Cushing’s Disease [PDF]

, 2008
Christiaan de Bruin, Jeanette Hanson, Björn P. Meij, H.S. Kooistra, A. M. Waaijers, André G. Uitterlinden, Steven W. J. Lamberts, Leo J. Hofland   +7 more
openalex   +1 more source

Bone metastases from neuroendocrine neoplasms: Results of an Italian nationwide survey of natural history and management

Journal of Neuroendocrinology, EarlyView.
Abstract Bone metastases (BMs) were reported in <15% of cases of neuroendocrine neoplasms (NENs). Their clinical behavior is various and clinical management is still undefined. This study aimed to describe the clinical practical management and survival outcome of neuroendocrine neoplasm patients with BMs.
Nicola Fazio, Patrick Maisonneuve, Anna Maria Frezza, Nicoletta Ranallo, Toni Ibrahim, Anna La Salvia, Maria Pia Brizzi, Chiara De Divitiis, Salvatore Tafuto, Sara Pusceddu, Riccardo Marconcini, Mauro Cives, Cristina Ferrari, Davide Campana, Delia De Lisi, Daniele Santini, Antongiulio Faggiano, Roberta Modica, Sara Massironi, Antonio Bianchi, Francesco Panzuto, Lorenzo Antonuzzo, Elisa Pellegrini, Vito Amoroso, Ivana Puliafito, Elettra Merola, Nicola Silvestris, Chiara Maria Grana, Francesca Spada   +28 more
wiley   +1 more source

Study protocol of LANTana: a phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]Lu-DOTA-TATE in patients with metastatic neuroendocrine tumours, UK. [PDF]

BMJ Open, 2023
Murphy R, Chander G, Martinez M, Ward C, Khan SR, Naik M, Barwick T, Aboagye E, Sharma R.   +8 more
europepmc   +1 more source

OR01-01 Oral, Once-daily, Paltusotine (Non-peptide Selective Somatostatin Receptor Subtype 2 Agonist) Therapy In Patients With Acromegaly Is Associated With Long-term Biochemical And Symptom Control And Is Preferred Over Injectable Somatostatin-Receptor Ligands

, 2023
Mônica R. Gadelha, Harpal Randeva, Murray B. Gordon, Mirjana Doknić, Emese Mezősi, Miklós Tóth, César Luiz Boguszewski, Christine Ferrara-Cook, Alessandra Casagrande, Alan Krasner   +9 more
openalex   +1 more source